|
Genentech Will Pay $20 Million to Settle Rituxan Whistleblower Case
Genentech has agreed to pony up $20 million to the U.S. government to settle a qui tam suit alleging kickbacks for off-label promotion of its cancer drug Rituxan.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives